Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages

Haematologica

Volumn 100, Issue 4, 2015, Pages e140-e142

  Borge, Mercedes ^a,b   Almejún, María Belén ^a   Podaza, Enrique ^a   Colado, Ana ^a   Grecco, Horacio Fernández ^c   Cabrejo, María ^c   Bezares, Raimundo F ^d   Giordano, Mirta ^a,b   Gamberale, Romina ^a,b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c Sanatorio Municipal Dr Julio Méndez CABA ^*  (Argentina)

^d Hospital General De Agudos Teodoro Alvarez   (Argentina)

Author keywords

Ibrutinib; Phagocytosis; Rituximab dependent

Indexed keywords

BREAKPOINT CLUSTER REGION PROTEIN; BRUTON TYROSINE KINASE; FGR KINASE; HEMATOPOIETIC CELL KINASE; IBRUTINIB; PHOSPHOTRANSFERASE; PROTEIN KINASE LYN; RITUXIMAB; T LYMPHOCYTE RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

APOPTOSIS; BINDING KINETICS; CHRONIC LYMPHATIC LEUKEMIA; CONFOCAL MICROSCOPY; DRUG EFFICACY; DRUG TOLERABILITY; FLOW CYTOMETRY; HUMAN; LETTER; LEUKEMIA CELL; MACROPHAGE; NONHUMAN; PHAGOCYTOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; TREATMENT RESPONSE; CELL PHAGOCYTOSIS; DRUG EFFECTS; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CYTOPHAGOCYTOSIS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MACROPHAGES; RITUXIMAB;

EID: 84926290880     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.119669     Document Type: Letter

References (14)

1. Davids MS, Brown JR. Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. Future Oncol. 2014;10(6):957-967.
2. de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor-and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119(11):2590-2594.
3. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287-6296.
4. Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539-2549.
5. Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014; 15(10):1090-1099.
6. Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptordependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199(12):1659-1669.
7. Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142(5):699-713.
8. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppa S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res. 2007;13(19):5784-5789.
9. Canioni D, Salles G, Mounier N, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol. 2008; 26(3):440-446.
10. Rafiq S, Butchar JP, Cheney C, et al. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol. 2013;190(6):2702-2711.
11. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075-13080.
12. Fitzer-Attas CJ, Lowry M, Crowley MT, et al. Fcgamma receptormediated phagocytosis in macrophages lacking the Src family tyrosine kinases Hck, Fgr, and Lyn. J Exp Med. 2000;191(4):669-682.
13. Kohrt HE, Sagiv-Barfi I, Rafiq S, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood. 2014; 123(12):1957-1960.
14. Da Roit F, Engelberts PJ, Taylor RP, et al. Ibrutinib interferes with the cell-mediated anti-tumour activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica. 2015; 100(1):77-86.